Main > ONCOLOGY (**) > Lung>NSCLC>MET>PD-L1+>> *** > Treatment > CH. R. AtezolizuMAb ***

---

CH. R. AtezolizuMAb ***'s subsections
(*) USA Approval Date: 2016. 10.18.
>Not Has Abnormal “EGFR”/“ALK" Gene
>Tried Pt-CT & Not Works & Tumor>
Company
Patent>Assignee; Claims; No.; Etc
Patent>UpDate: 2017. 04.18.
PR Web-Site
TradeMark
TradeMark Web-Site
UpDate: 2017. 09.03

CH. R. AtezolizuMAb ***'s products
This section has no products